; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) address unmet and underserved medical needs in women's health. Our product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:

  • JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
  • JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
  • JNP-0301, a natural progesterone IVR for the prevention of preterm birth.

Our R&D programs are supported by cash flow generated by Crinone® (progest  More >>

Stock Quote

JNP (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Up 0.05 (1.11%)
Data as of 08/18/17 4:00 p.m. ET
Minimum 20 minute delayRefresh quote
JNP Corporate Overview
Recent NewsMore >>
08/03/17Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating ResultsPrinter Friendly Version
07/27/17Juniper Pharmaceuticals to Report Second Quarter 2017 Results on August 3, 2017Printer Friendly Version
07/05/17Juniper Pharmaceuticals Announces Results of 2017 Annual MeetingPrinter Friendly Version
05/04/17Juniper Pharmaceuticals Reports First Quarter 2017 Financial and Operating ResultsPrinter Friendly Version